Pacira Biosciences Inc
NASDAQ:PCRX

Watchlist Manager
Pacira Biosciences Inc Logo
Pacira Biosciences Inc
NASDAQ:PCRX
Watchlist
Price: 19.91 USD 0.3% Market Closed
Market Cap: $856.5m

Operating Margin

8.9%
Current
Declining
by 2.8%
vs 3-y average of 11.7%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
8.9%
=
Operating Income
$63.6m
/
Revenue
$716.8m

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
8.9%
=
Operating Income
$63.6m
/
Revenue
$716.8m

Peer Comparison

Country Company Market Cap Operating
Margin
US
Pacira Biosciences Inc
NASDAQ:PCRX
849m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
954.9B USD
Loading...
US
Johnson & Johnson
NYSE:JNJ
546.2B USD
Loading...
CH
Roche Holding AG
SIX:ROG
268.4B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
209.9B GBP
Loading...
CH
Novartis AG
SIX:NOVN
219B CHF
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.7T DKK
Loading...
US
Merck & Co Inc
NYSE:MRK
265.4B USD
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
147.6B USD
Loading...
FR
Sanofi SA
PAR:SAN
94.4B EUR
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
57th
Based on 14 112 companies
57th percentile
8.9%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Pacira Biosciences Inc
Glance View

Market Cap
856.5m USD
Industry
Pharmaceuticals

Pacira Biosciences, Inc. is a holding company, which provide non-opioid pain management and regenerative health solutions to improve patients’ journeys along the neural pain pathway. The company is headquartered in Tampa, Florida and currently employs 697 full-time employees. The company went IPO on 2011-02-03. The firm is focused on the development, manufacture, marketing, distribution and sale of non-opioid pain management and regenerative health solutions. Its product candidate, EXPAREL (bupivacaine liposome injectable suspension) provides postsurgical analgesia and reduces the consumption of opioid medications. EXPAREL consists of bupivacaine, an amide-type local anesthetic, encapsulated in DepoFoam, an extended-release drug delivery technology, that delivers bupivacaine over time for extended analgesia. Its ZILRETTA (triamcinolone acetonide extended-release injectable suspension) is an extended-release, intra-articular, injection indicated for the management of osteoarthritis knee pain. Its iovera is a handheld device for delivering immediate, long-acting, drug-free pain control using precise, controlled doses of cold temperature to a targeted nerve.

PCRX Intrinsic Value
52.12 USD
Undervaluation 62%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
8.9%
=
Operating Income
$63.6m
/
Revenue
$716.8m
What is Pacira Biosciences Inc's current Operating Margin?

The current Operating Margin for Pacira Biosciences Inc is 8.9%, which is below its 3-year median of 11.7%.

How has Operating Margin changed over time?

Over the last 3 years, Pacira Biosciences Inc’s Operating Margin has decreased from 15.7% to 8.9%. During this period, it reached a low of 8.7% on Mar 31, 2023 and a high of 15.7% on Sep 30, 2022.

Back to Top